Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07816198

A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Type 2 Diabetes Mellitus (T2DM) Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

About this study

Condition or disease: Type 2 Diabetes Mellitus

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Other inclusions applied

Exclusion criteria

  • Subjects with severe diabetic complications
  • Other exclusions applied

Treatment and study plan

AD-233A

Drug

PO, Once daily(QD), 24 weeks

AD-233B

Drug

PO, Once daily(QD), 24 weeks

AD-233C

Drug

PO, Once daily(QD), 24 weeks

AD-233D

Drug

PO, Once daily(QD), 24 weeks

AD-233A Placebo

Drug

PO, Once daily(QD), 24 weeks

AD-233B Placebo

Drug

PO, Once daily(QD), 24 weeks

Primary outcomes

  1. Change in HbA1c from baseline at Week 24 after administration of IP

    Time frame: Baseline, Week 24

Study contacts

Contact information is provided by the study sponsor or research team.

Hanna Yang

CONTACT

[email protected]

82+01084267236

Seong rae Kim, Principal Investigator

CONTACT

Sponsors and collaborators

Lead sponsor

Addpharma Inc.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy in Patients With Type 2 Diabetes Mellitus

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Sep 11, 2026
Registry last updated
Sep 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.